192 related articles for article (PubMed ID: 34130573)
1. Clinical, patient and estimated cost benefits of proactive management versus reactive management with calcipotriol/betamethasone dipropionate foam for the treatment of plaque psoriasis in Finland.
Harvima RJ; Gooderham M; Tyring S; Thoning H; Nyholm N; Stein Gold L
J Dermatolog Treat; 2022 Jun; 33(4):2234-2240. PubMed ID: 34130573
[TBL] [Abstract][Full Text] [Related]
2. Twice-weekly topical calcipotriene/betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial).
Lebwohl M; Kircik L; Lacour JP; Liljedahl M; Lynde C; Mørch MH; Papp KA; Perrot JL; Gold LS; Takhar A; Thaçi D; Warren RB; Wollenberg A
J Am Acad Dermatol; 2021 May; 84(5):1269-1277. PubMed ID: 32950546
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of proactive treatment with twice-weekly topical Cal/BD foam in patients with plaque psoriasis undergoing HPA-axis testing: a PSO-LONG subgroup analysis.
Papp K; Adamski Z; Guenther L; Liljedahl M; Miasik-Pogodzinska A; Szponar-Bojda A; Lynde C; Nutt T; Mørch MH; Tyring S; Werschler W; Reich A; Sadick N; Turchin I; Lacour JP
J Dermatolog Treat; 2022 Jun; 33(4):2297-2304. PubMed ID: 34365872
[TBL] [Abstract][Full Text] [Related]
4. A cost-effectiveness analysis of calcipotriol plus betamethasone dipropionate aerosol foam versus gel for the topical treatment of plaque psoriasis.
Foley P; Garrett S; Ryttig L
Curr Med Res Opin; 2018 Jul; 34(7):1277-1283. PubMed ID: 29336190
[TBL] [Abstract][Full Text] [Related]
5. PSO-LONG: Design of a Novel, 12-Month Clinical Trial of Topical, Proactive Maintenance with Twice-Weekly Cal/BD Foam in Psoriasis.
Stein Gold L; Alonso-Llamazares J; Lacour JP; Warren RB; Tyring SK; Kircik L; Yamauchi P; Lebwohl M;
Adv Ther; 2020 Nov; 37(11):4730-4753. PubMed ID: 32965655
[TBL] [Abstract][Full Text] [Related]
6. Quality of life and patient-perceived symptoms in patients with psoriasis undergoing proactive or reactive management with the fixed-dose combination Cal/BD foam: A post-hoc analysis of PSO-LONG.
Jalili A; Calzavara-Pinton P; Kircik L; Lons-Danic D; Pink A; Tyring S; de la Cueva P; Gooderham M; Segaert S; Nyholm N; Thoning H; Petersen B; Thaçi D
J Eur Acad Dermatol Venereol; 2022 Jan; 36(1):60-67. PubMed ID: 34543474
[TBL] [Abstract][Full Text] [Related]
7. The Effect on BSA of Proactive Management versus Reactive Management of Psoriasis With Fixed-Dose Cal/BD Foam in the PSO-LONG Study.
Takhar A; Thoning H; Nyholm N; Petersen B; Stein Gold L
J Drugs Dermatol; 2021 May; 20(5):567-570. PubMed ID: 33938704
[TBL] [Abstract][Full Text] [Related]
8. Rapid onset of action of calcipotriol/betamethasone dipropionate cutaneous foam in psoriasis, even in patients with more severe disease.
Pink AE; Jalili A; Berg P; Calzavara-Pinton PG; de la Cueva Dobao P; Thaçi D; Torpet M; Jensen KL; Segaert S
J Eur Acad Dermatol Venereol; 2019 Jun; 33(6):1116-1123. PubMed ID: 30916417
[TBL] [Abstract][Full Text] [Related]
9. A Cost-utility Analysis of Calcipotriol/Betamethasone Dipropionate Aerosol Foam versus Ointment for the Topical Treatment of Psoriasis Vulgaris in Sweden.
Duvetorp A; Levin LÅ; Engerstedt Mattsson E; Ryttig L
Acta Derm Venereol; 2019 Apr; 99(4):393-399. PubMed ID: 30628631
[TBL] [Abstract][Full Text] [Related]
10. Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis: Sub-Group Analysis of the PSO-ABLE Study.
Paul C; Leonardi C; Menter A; Reich K; Gold LS; Warren RB; Møller A; Lebwohl M
Am J Clin Dermatol; 2017 Jun; 18(3):405-411. PubMed ID: 28236223
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam in Patients With Psoriasis Vulgaris--a Randomized Phase III Study (PSO-FAST).
Leonardi C; Bagel J; Yamauchi P; Pariser D; Xu Z; Olesen M; Østerdal ML; Stein Gold L
J Drugs Dermatol; 2015 Dec; 14(12):1468-77. PubMed ID: 26659941
[TBL] [Abstract][Full Text] [Related]
12. Calcipotriol plus betamethasone dipropionate aerosol foam vs. apremilast, methotrexate, acitretin or fumaric acid esters for the treatment of plaque psoriasis: a matching-adjusted indirect comparison.
Bewley AP; Shear NH; Calzavara-Pinton PG; Hansen JB; Nyeland ME; Signorovitch J
J Eur Acad Dermatol Venereol; 2019 Jun; 33(6):1107-1115. PubMed ID: 30472749
[TBL] [Abstract][Full Text] [Related]
13. Greater improvement in quality of life outcomes in patients using fixed-combination calcipotriol plus betamethasone dipropionate aerosol foam versus gel: results from the PSO-ABLE study.
Griffiths CE; Stein Gold L; Cambazard F; Kalb RE; Lowson D; Møller A; Paul C
Eur J Dermatol; 2018 Jun; 28(3):356-363. PubMed ID: 29952297
[TBL] [Abstract][Full Text] [Related]
14. Impact of fixed-dose combination Cal/BD foam on the work productivity of patients with psoriasis: results from the 52-week randomized, double-blind, PSO-LONG trial.
Guenther L; Takhar A; Megna M; Sebastian M; Nyholm N; Thoning H; Levin LÅ
J Eur Acad Dermatol Venereol; 2022 Jul; 36(7):1054-1063. PubMed ID: 35297108
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness comparison and incremental cost-per-responder analysis of calcipotriene 0.005%/betamethasone dipropionate 0.064% foam vs. halobetasol 0.01%/tazarotene 0.045% lotion for plaque psoriasis: a matching-adjusted indirect comparative analysis.
Wu JJ; Hansen JB; Patel DS; Nyholm N; Veverka KA; Swensen AR
J Med Econ; 2020 Jun; 23(6):641-649. PubMed ID: 31985301
[No Abstract] [Full Text] [Related]
16. Cost per PASI-75 responder of calcipotriol plus betamethasone dipropionate cutaneous foam versus nonbiologic systemic therapies for the treatment of plaque psoriasis in seven European countries.
Balak DMW; Carrascosa JM; Gregoriou S; Calzavara-Pinton P; Bewley A; Antunes J; Nyeland ME; Viola MG; Sawyer LM; Becla L
J Dermatolog Treat; 2021 Nov; 32(7):701-708. PubMed ID: 31940225
[TBL] [Abstract][Full Text] [Related]
17. Calcipotriol/betamethasone dipropionate aerosol foam in the treatment of psoriasis: new perspectives for the use of an innovative topical treatment from real-life experience.
Fabbrocini G; Dauden E; Jalili A; Bewley A
G Ital Dermatol Venereol; 2020 Apr; 155(2):212-219. PubMed ID: 32394674
[TBL] [Abstract][Full Text] [Related]
18. Matching-adjusted indirect comparison of efficacy outcomes in trials of calcipotriol plus betamethasone dipropionate foam and cream formulations for the treatment of plaque psoriasis.
Papp KA; Thoning H; Gerdes S; Megna M; Brandi H; Jablonski Bernasconi MY; Yélamos O
J Dermatolog Treat; 2022 Nov; 33(7):3005-3013. PubMed ID: 35875991
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of an innovative aerosol foam formulation of fixed combination calcipotriol plus betamethasone dipropionate in patients with psoriasis vulgaris.
Queille-Roussel C; Olesen M; Villumsen J; Lacour JP
Clin Drug Investig; 2015 Apr; 35(4):239-45. PubMed ID: 25708531
[TBL] [Abstract][Full Text] [Related]
20. PGAxBSA composite versus PASI: Comparison across disease severities and as therapeutic response measure for Cal/BD foam in plaque psoriasis.
Gold LS; Hansen JB; Patel D; Veverka KA; Strober B
J Am Acad Dermatol; 2020 Jul; 83(1):131-138. PubMed ID: 32430142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
